Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers

This policy covers specific named MRD tests (both bespoke/tumor-informed and tumor‑naïve single‑plasma assays) for defined indications in patients with and without cancer when used consistent with each test's validated claims and when medical necessity is documented per the related LCD. Coverage requires DEX registration and submission of the assigned DEX Z‑Code with the claim, billing of 1 unit of service, and adherence to frequency limits (generally one UOS per episode; for patients with cancer, generally once per diagnosis unless an a priori genetic change is documented).

"Initial MRD testing using Signatera Bespoke Assay Design plus Plasma Series Bundle (Natera, Inc."

Sign up to see full coverage criteria, indications, and limitations.